vs
Side-by-side financial comparison of Evolent Health, Inc. (EVH) and TOWER SEMICONDUCTOR LTD (TSEM). Click either name above to swap in a different company.
Evolent Health, Inc. is the larger business by last-quarter revenue ($496.2M vs $351.2M, roughly 1.4× TOWER SEMICONDUCTOR LTD). TOWER SEMICONDUCTOR LTD runs the higher net margin — 15.2% vs -5.4%, a 20.6% gap on every dollar of revenue. On growth, Evolent Health, Inc. posted the faster year-over-year revenue change (2.6% vs -1.7%).
Magellan Health Inc., is an American for-profit managed health care company and subsidiary of Centene that focuses on special populations and other specialty areas of healthcare. Magellan's customers include health plans and other managed care organizations, employers, labor unions, various military and governmental agencies and third-party administrators. It ranked 390 on the Fortune 500 in 2021.
Tower Semiconductor Ltd. is an Israeli company that manufactures integrated circuits using specialty process technologies, including SiGe, BiCMOS, Silicon Photonics, SOI, mixed-signal and RFCMOS, CMOS image sensors, non-imaging sensors, power management (BCD), and non-volatile memory (NVM) as well as MEMS capabilities. Tower Semiconductor also owns 51% of TPSCo, an enterprise with Nuvoton Technology Corporation Japan (NTCJ).
EVH vs TSEM — Head-to-Head
Income Statement — Q1 FY2026 vs Q2 FY2024
| Metric | | |
|---|---|---|
| Revenue | $496.2M | $351.2M |
| Net Profit | $-26.6M | $53.4M |
| Gross Margin | 16.9% | 24.8% |
| Operating Margin | — | 15.7% |
| Net Margin | -5.4% | 15.2% |
| Revenue YoY | 2.6% | -1.7% |
| Net Profit YoY | — | 4.4% |
| EPS (diluted) | — | $0.48 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $496.2M | — | ||
| Q4 25 | $468.7M | — | ||
| Q3 25 | $479.5M | — | ||
| Q2 25 | $444.3M | — | ||
| Q1 25 | $483.6M | — | ||
| Q4 24 | $646.5M | — | ||
| Q3 24 | $621.4M | — | ||
| Q2 24 | $647.1M | $351.2M |
| Q1 26 | $-26.6M | — | ||
| Q4 25 | $-429.1M | — | ||
| Q3 25 | $-20.9M | — | ||
| Q2 25 | $-19.9M | — | ||
| Q1 25 | $-64.6M | — | ||
| Q4 24 | $-22.8M | — | ||
| Q3 24 | $-23.1M | — | ||
| Q2 24 | $1.6M | $53.4M |
| Q1 26 | 16.9% | — | ||
| Q4 25 | 20.7% | — | ||
| Q3 25 | 20.8% | — | ||
| Q2 25 | 22.6% | — | ||
| Q1 25 | 21.2% | — | ||
| Q4 24 | 11.7% | — | ||
| Q3 24 | 13.0% | — | ||
| Q2 24 | 16.5% | 24.8% |
| Q1 26 | — | — | ||
| Q4 25 | -87.1% | — | ||
| Q3 25 | 0.2% | — | ||
| Q2 25 | -0.3% | — | ||
| Q1 25 | -0.3% | — | ||
| Q4 24 | -2.9% | — | ||
| Q3 24 | -2.6% | — | ||
| Q2 24 | 1.2% | 15.7% |
| Q1 26 | -5.4% | — | ||
| Q4 25 | -91.6% | — | ||
| Q3 25 | -4.4% | — | ||
| Q2 25 | -4.5% | — | ||
| Q1 25 | -13.4% | — | ||
| Q4 24 | -3.5% | — | ||
| Q3 24 | -3.7% | — | ||
| Q2 24 | 0.2% | 15.2% |
| Q1 26 | — | — | ||
| Q4 25 | $-3.76 | — | ||
| Q3 25 | $-0.24 | — | ||
| Q2 25 | $-0.44 | — | ||
| Q1 25 | $-0.63 | — | ||
| Q4 24 | $-0.26 | — | ||
| Q3 24 | $-0.27 | — | ||
| Q2 24 | $-0.06 | $0.48 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $142.0M | $265.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $396.4M | $2.5B |
| Total Assets | $1.9B | $3.0B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $142.0M | — | ||
| Q4 25 | $151.9M | — | ||
| Q3 25 | $116.7M | — | ||
| Q2 25 | $151.0M | — | ||
| Q1 25 | $246.5M | — | ||
| Q4 24 | $104.2M | — | ||
| Q3 24 | $96.6M | — | ||
| Q2 24 | $101.3M | $265.3M |
| Q1 26 | $396.4M | — | ||
| Q4 25 | $415.2M | — | ||
| Q3 25 | $842.2M | — | ||
| Q2 25 | $896.0M | — | ||
| Q1 25 | $935.5M | — | ||
| Q4 24 | $1.0B | — | ||
| Q3 24 | $1.0B | — | ||
| Q2 24 | $1.1B | $2.5B |
| Q1 26 | $1.9B | — | ||
| Q4 25 | $1.9B | — | ||
| Q3 25 | $2.5B | — | ||
| Q2 25 | $2.5B | — | ||
| Q1 25 | $2.7B | — | ||
| Q4 24 | $2.5B | — | ||
| Q3 24 | $2.5B | — | ||
| Q2 24 | $2.5B | $3.0B |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
EVH
| Performance Suite | $323.3M | 65% |
| Specialty Technology and Services Suite | $80.8M | 16% |
| Administrative Services | $49.6M | 10% |
| Cases | $42.6M | 9% |
TSEM
Segment breakdown not available.
